SOLO-1 Lynparza Data In First-Line Ovarian Cancer Seen Boosting AstraZeneca's PARP Edge

 
• By Sten Stovall
Ovarian cancer
Lynparza tablets showed statistically significant, clinically meaningful improvement in PFS vs placebo • Source: Shutterstock

More from Clinical Trials

More from R&D